Study Assessing Long-term Safety and Efficacy of Alpelisib in Patients With PIK3CA-Related Overgrowth Spectrum (PROS) Who Previously Participated in Study CBYL719F12002 (EPIK-P1)
Clinical trial NCT04980833 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04980833
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-01-27
- Primary completion
- 2027-08-20
- Enrollment
- 41
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.